February 22nd 2024
Findings from the phase 3b OReO study showed that patients with ovarian cancer who previously received a PARP inhibitor benefitted from a rechallenge with olaparib.
February 15th 2024
February 2nd 2024
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board